[at Bloomberg] – Abbott Laboratories (ABT) and AbbVie Inc., the company it spun off last year, hid the dangers of using the testosterone replacement drug AndroGel, five men claimed in lawsuits. Their complaints, filed …
Read more on this.
Abbott Laboratories (ABT), with a current market cap of $56.31B, started trading this morning at $36.12.
During today’s session, ABT traded between $35.98 to $36.60 and has traded between $32.70 and $39.86 over the past year.
ABT shares are currently priced at 16.48x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 9.65x earnings multiple for the same period.
And for dividend hunters, the company pays shareholders $0.88 per share annually in dividends, yielding 2.40%.
In a review of the consensus earnings estimate this quarter, 19 sell-side analysts are looking at $0.36 per share, which would be $0.06 worse than the year-ago quarter and a $0.13 sequential decrease. The full-year EPS estimate is $2.20, which would be a $0.19 better than last year.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $5.30 Billion. If realized, that would be a 1.49% decrease over the year-ago quarter.
More recently, Gabelli & Co Initiated ABT at Buy (May 21, 2013). Previously, Stifel Nicolaus Initiated ABT at to Buy.
The average price target for ABT shares is $41.93, which is 16.09% above where the stock opened this morning.
Abbott Laboratories (NYSE:ABT), engages in the discovery, development, manufacture, and sale of health care products worldwide. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians offices, and government agencies. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Tag Helper ~ Stock Code: ABT | Common Company name: Abbott Labs | Full Company name: Abbott Laboratories (NYSE:ABT) .